| Literature DB >> 32363222 |
Juan Chen1, Zhen-Zhen Zhang2, Yao-Kai Chen3, Quan-Xin Long1, Wen-Guang Tian4, Hai-Jun Deng1, Jie-Li Hu1, Xian-Xiang Zhang5, Jiang-Lin Xiang6, Dao-Xin Wang7, Peng Hu1, Fa-Chun Zhou8, Zhi-Jie Li5, Hong-Mei Xu2, Xue-Fei Cai1, De-Qiang Wang1, Yuan Hu1, Ni Tang1, Bei-Zhong Liu9, Gui-Cheng Wu10, Ai-Long Huang1.
Abstract
In December 2019, the corona virus disease 2019 (COVID-19) caused by novel coronavirus (SARS-CoV-2) emerged in Wuhan, China and rapidly spread worldwide. Few information on clinical features and immunological profile of COVID-19 in paediatrics. The clinical features and treatment outcomes of twelve paediatric patients confirmed as COVID-19 were analyzed. The immunological features of children patients was investigated and compared with twenty adult patients. The median age was 14.5-years (range from 0.64 to 17), and six of the patients were male. The average incubation period was 8 days. Clinically, cough (9/12, 75%) and fever (7/12, 58.3%) were the most common symptoms. Four patients (33.3%) had diarrhea during the disease. As to the immune profile, children had higher amount of total T cell, CD8+ T cell and B cell but lower CRP levels than adults (P < 0.05). Ground-glass opacity (GGO) and local patchy shadowing were the typical radiological findings on chest CT scan. All patients received antiviral and symptomatic treatment and the symptom relieved in 3-4 days after admitted to hospital. The paediatric patients showed mild symptom but with longer incubation period. Children infected with SARS-CoV-2 had different immune profile with higher T cell amount and low inflammatory factors level, which might ascribed to the mild clinical symptom. We advise that nucleic acid test or examination of serum IgM/IgG antibodies against SARS-CoV-2 should be taken for children with exposure history regardless of clinical symptom.Entities:
Keywords: COVID-19; Clinical features; Immune; Paediatrics; SARS-CoV-2
Year: 2020 PMID: 32363222 PMCID: PMC7194810 DOI: 10.1016/j.gendis.2020.03.008
Source DB: PubMed Journal: Genes Dis ISSN: 2352-3042
Figure 1Timeline of from exposure to onset of symptom in SARS-CoV-2-infected paediatric patients.
Clinical characteristics of twelve paediatric patients infected with SARS-CoV-2.
| Overall, Mean (±SD) | |
|---|---|
| Age, median (25th-75th percentile), y | 14.50 (9.25–15.75) |
| Gender (%) | |
| Male | 6 (50) |
| Female | 6 (50) |
| Exposure History (%) | |
| Contact with confirmed case | 8(67.7) |
| Local residents of Wuhan | 3 (25) |
| Travelled to Wuhan | 1(8.3) |
| Fever | 7 (58.3) |
| Febrile days | 5.29 ± 4.300 |
| Maximum temperature, °C | 38.27 ± 0.411 |
| Cough, No. (%) | 9 (75) |
| Diarrhea, No. (%) | 4(33.3) |
| Upper airway symptom, No. (%) | 2(16.7) |
| Dizziness, No. (%) | 2(16.7) |
| Fatigue, No. (%) | 1(8.3) |
| Hemoglobin, g/L (normal range 120–160) | 130.30 ± 13.84 |
| Platelets, × 109/L (normal range 125–350) | 278.60 ± 133.340 |
| WBC cells, × 109/L (normal range 3.5–9.5) | 6.33 ± 1.78 |
| ALT, U/L (normal range 7–40) | 28.8±16.5 |
| AST, U/L (normal range 14–36) | 23.8±7.77 |
| CK-MB,U/L (normal range 0–25) | 14.7±8.13 |
| sCr, umol/L (normal range 62–106) | 54.5±18.72 |
| BUN,mmol/L (normal range 2.5–6.1) | 3.44±0.83 |
| PT, s (normal range 8–14) | 13.5±2.15 |
Abbreviations: WBC: white blood cell; ALT:Alanine aminotransferase; AST: Aspartate aminotransferase; CK-MB: creatine kinase isoenzymes,sCr:Serum creatinine.BUN: bloodUrea nitrogen,PT: prothrombin time.
Figure 2The dynamic changes of clinical laboratory parameters, including WBC (A), lymphocytes (B) and platelet count (C), in 3 paediatric patients infected with SARS-CoV-2 based on days after disease onset.
The level of T cell and its subgroups, antibodies, compliment 3, and inflammatory markers in paediatrics and adults groups.
| Paediatrics ( | Adults ( | ||
|---|---|---|---|
| Total T cells (x109/L) | 2.13 ± 0.72 | 1.06 ± 0.53 | <0.0001 |
| CD4+ T cells (cells/ul) | 598.10 ± 215.10 | 425.50 ± 278.10 | 0.0596 |
| CD8+ T cells (cells/ul) | 442.50 ± 117.50 | 246.80 ± 144.10 | 0.0068 |
| Total B cells (x106/L) | 194.70 ± 75.42 | 120.9 ± 57.89 | 0.0284 |
| NK cells(x106/L) | 208.2±117.4 | 191.2±87.91 | 1 |
| IgM(g/L) | 1.22±0.39 | 1.03±0.41 | 0.2515 |
| IgG(g/L) | 10.86±1.44 | 11.85±4.51 | 0.9805 |
| C3(g/L) | 1.37 ± 0.10 | 1.35±0.22 | 0.9416 |
| IL-6 (ng/ml) | 8.44 ± 2.65 | 20.51 ± 5.19 | 0.0842 |
| CRP (mg/L) | 11.51 ± 2.39 | 23.34 ± 2.84 | 0.0251 |
| PCT(ng/ml) | 0.18 ± 0.066 | 0.11 ± 0.025 | 0.3136 |
Statistics significance.
Figure 3Chest CT images of two patients. (A) Patient 1 was a 16 year-old male patient with fever. CT test showed ground-glass opacity in the right lung. (B) Patient 2 was a 14 year-old male with fever and cough. CT scan showed ground-glass opacity and local patchy shadowing in the right lung.